



Infliximab for IBD: What You Need to Know

WHAT IS INFlixIMAB?

- A biologic medication used to treat **Crohn's disease** and **ulcerative colitis (UC)**.
- Infliximab is an extensively studied, well tolerated, and effective medication for the treatment of IBD.
- The initial formulation of infliximab known as Remicade® has been used for over twenty years.



HELPS:



HOW DOES IT WORK?

- Targets tumor necrosis factor-alpha (TNF- α), a protein responsible for inflammation.
- Binds to TNF- α and blocks it from triggering the immune response.
- Helps the digestive tract heal and reduces overall immune system overactivity.⁸

Abnormal connections between the intestines and other tissues.⁵

Joint pain, eye inflammation & skin conditions.⁶

WHAT ARE BIOSIMILARS?



- Biosimilars are **near-identical** versions of biologics, created after the patent of the original drug expires. They are proven to be as **safe** and **effective** as biologics.
- Infliximab biosimilars of the originator infliximab biologic **Remicade®** approved in Canada include:
 - Inflectra® (2016)
 - Renflexis® (2017)

EFFECTIVENESS & SAFETY

- Well-studied with over 20 years of data on long-term use.
- Reduces the risk of:
 - Flare-ups and hospitalizations
 - Surgery for Crohn's or UC
- Potential side effects include infections, and allergic reactions. These side effects are rare, and risk can be reduced with proper preventative measures.⁷


HOW IS IT ADMINISTERED?



-
- The diagram is split into two panels. The left panel, labeled 'Intravenous', shows a person with red hair in a blue shirt standing next to an IV stand. A clear plastic IV bag hangs from the stand, with a tube leading to the person's arm. The right panel, labeled 'Subcutaneous', shows a close-up of a syringe with a needle inserted into a layer of skin, represented by wavy orange and yellow lines.

Intravenous (IV) Infliximab	
Administration	• Through an IV infusion at a clinic or hospital
Dosing Schedule	• Typically at weeks 0, 2, and 6, then every 8 weeks for maintenance. • Ongoing infusions may be given more frequently if a patient's Gastroenterologist decides this is needed.
Benefits	• Administered by healthcare professionals, ensuring proper dosing and monitoring. Ideal for patients who prefer a hands-off approach or require higher doses for disease control.

Subcutaneous (SC) Infliximab	
Administration	Self-injected under the skin usually into the thigh, abdomen, or upper arm using a pre-filled syringe or auto-injector.
Dosing Schedule	- Induction Phase: Patients start with 5 mg/kg intravenous (IV) infliximab at weeks 0, 2, and 6 to rapidly reduce inflammation. - Maintenance Phase: At week 8, patients transition to subcutaneous (SC) injections every 2 weeks for ongoing treatment.
Benefits	Convenient for at-home use. Ideal for patients looking for flexibility in managing their treatment.



HEALTHCARE
CELLTRION